Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.41M.
Fairly Valued
The company’s latest PE is -1.28, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.06M shares, decreasing 27.30% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 10.16K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.57.